NR4A1 and neoplasm: DESTINY-Breast 04 was the first open label randomised controlled phase 3 trial for T-DXd for advanced and all metastatic HER2-low breast cancer including both hormonal receptor positive (n = 494, 88.7%) and negative (n = 63, 11.3%) tumours.